Imlifidase & IgG-Cleaving Enzymes — PatSnap Eureka
Imlifidase & IgG-Cleaving Enzymes in Kidney Transplant Desensitization
Approximately 20–30% of waitlisted US kidney transplant candidates are HLA-sensitized, facing prolonged wait times and elevated antibody-mediated rejection risk. IgG-cleaving enzymes like imlifidase (IdeS) represent a mechanistically distinct approach to rapidly neutralizing donor-specific antibodies before and after transplantation.
The Immunological Barrier to Kidney Transplantation
Antibody-mediated rejection (AMR) is the primary driver of long-term allograft failure. The central immunological barrier is the presence of pre-formed or de novo donor-specific antibodies (DSAs) directed against human leukocyte antigens (HLA) expressed on the vascular endothelium and tubular cells of transplanted kidneys. DSA binding activates the classical complement cascade, culminating in endothelial injury, transplant glomerulopathy (TG), and chronic active ABMR (cABMR).
PatSnap's life sciences intelligence platform has tracked multiple converging patent families addressing this problem. IL-6 is identified as a pivotal cytokine sustaining DSA-producing plasma cells and driving allograft inflammation, with clazakizumab (an anti-IL-6 antibody) demonstrating reduced DSA levels in HLA-sensitized patients awaiting kidney transplant.
Complement component C5 is identified as a downstream effector target. The terminal complement membrane attack complex (MAC), generated after C5 cleavage, mediates acute endothelial damage. Separately, C1 esterase inhibitor (C1-INH) addresses the more proximal classical and lectin complement pathways, with patent filings from Shire ViroPharma and Cedars-Sinai claiming long-term eGFR improvement after kidney transplant.
A mechanistically distinct IgG-level target is introduced by Hansa BioPharma through the IdeS (Imlifidase) enzyme, which cleaves IgG at the hinge region, eliminating both Fc-receptor binding and complement fixation. According to WIPO filings, this approach represents one of the most novel mechanisms in the transplant desensitization space.
CD38-expressing plasma cells are identified as a cellular source of pathogenic DSA. Cedars-Sinai Medical Center has patented anti-CD38 antibody methods (including daratumumab) as a desensitization strategy specifically for patients refractory to standard-of-care plasmapheresis and IVIG.
Five Mechanistic Approaches to Desensitization & AMR
Retrieved patent and literature data cover IgG protease platforms, anti-IL-6 biologics, complement pathway inhibitors, anti-CD38 agents, and combination desensitization regimens as the principal therapeutic modalities in this space.
IgG-Cleaving Enzyme Therapy (Imlifidase / IdeS)
IdeS (Imlifidase), a streptococcal cysteine protease, cleaves human IgG at the lower hinge region, generating F(ab')₂ and Fc fragments. This eliminates Fc-receptor-mediated effector functions, complement fixation via C1q, and ADCC. In sensitized recipients, this cleavage transiently but profoundly reduces functional DSA titers, enabling a crossmatch-negative window for transplantation. Hansa Biopharma's conditioning regimen patent discloses that imlifidase preferentially cleaves DSA-IgG3 subclass (~80% reduction in murine models), with EndoS complementing by deglycosylating residual imlifidase-resistant IgG molecules.
~80% IgG3 DSA reduction (preclinical)Anti-IL-6 Antibody Therapy (Clazakizumab)
IL-6 promotes plasma cell survival, DSA production, and allograft inflammation. Clazakizumab, an anti-IL-6 antibody, blocks IL-6 signaling, reducing both circulating DSA and inflammatory markers of cABMR. Cedars-Sinai Medical Center has filed clazakizumab-based desensitization and AMR treatment patents across US, WO, CA, AU, BR, and JP jurisdictions. Key claims include pre-transplant desensitization of HLA-sensitized patients and treatment of chronic active ABMR with stabilization of eGFR at 6, 12, and 18 months post-treatment. Vitaeris Corp. holds a parallel WO patent family covering solid organ transplants including kidney, heart, liver, lung, pancreas, and intestine.
eGFR stabilized at 6–18 months (human cohort)Anti-C5 & C1 Esterase Inhibitor Strategies
Alexion Pharmaceuticals holds patents claiming methods for reducing AMR through phased, post-reperfusion anti-C5 antibody dosing in recipients who received ≥2 weeks of desensitization therapy prior to transplantation. Retrieved results note only 1/16 (6%) of sensitized recipients receiving anti-C5 antibody developed acute AMR within the first month versus ~40% of historical controls. Shire ViroPharma and CSL Behring patents cover C1-INH (Cinryze, Ruconest, Berinert) for proximal classical and lectin pathway complement inhibition. A Cedars-Sinai patent describes significantly reduced dialysis requirement at weeks 2 and 4 post-transplant and improved eGFR at 1 year with C1-INH.
6% vs ~40% acute AMR (anti-C5, n=16)Anti-CD38 Therapy (Daratumumab)
CD38 is highly expressed on long-lived plasma cells producing DSA. Anti-CD38 antibodies such as daratumumab deplete this cellular DSA source, providing a complementary mechanism to DSA-clearance strategies. Cedars-Sinai Medical Center's US patent positions anti-CD38 therapy specifically for patients refractory to IVIG and plasmapheresis (drug-resistant sensitization), representing an escalation strategy in the desensitization cascade. This represents a potential white space for biopharmaceutical developers with CD38-targeting assets in oncology seeking transplant label extensions.
Escalation for IVIG/plasmapheresis-refractory patientsKey Clinical & Patent Data Signals
Visualising the quantitative evidence from retrieved patent filings and clinical data referenced in patent specifications.
Acute AMR Incidence: Anti-C5 vs Historical Controls
Only 1/16 (6%) of sensitized recipients receiving anti-C5 antibody developed acute AMR within the first month, versus ~40% of historical controls — though ~50% developed transplant glomerulopathy after cessation.
IgG DSA Reduction: Imlifidase + EndoS Combination
Hansa Biopharma's conditioning regimen patent discloses ~80% reduction in DSA-IgG3 in sensitized murine models, with EndoS deglycosylating imlifidase-resistant IgG molecules for dual-mechanism effector silencing.
Who Holds the Key Patents in This Space?
Activity is predominantly patent-driven, concentrated among a small number of US academic medical centers and biopharmaceutical companies. Cedars-Sinai and Hansa Biopharma dominate their respective mechanistic niches.
Monitor AstraZeneca's IgG protease IP encroachment on Hansa's position
PatSnap Eureka tracks claim-level overlap across the IgG-cleaving enzyme patent landscape in real time.
Emerging Combination Strategies & Strategic Implications
No single modality provides durable protection against both acute AMR and long-term transplant glomerulopathy. Retrieved results signal several combination strategies as active development directions.
Imlifidase + EndoS: Dual-Mechanism IgG Silencing
The Hansa Biopharma conditioning regimen patent explicitly discloses the rationale for combining IdeS (cleaves IgG, especially IgG3) with EndoS (deglycosylates Fc of imlifidase-resistant IgG molecules), producing dual-mechanism IgG effector silencing. This combination addresses incomplete DSA elimination by either enzyme alone.
Anti-IL-6 + IVIG + Plasmapheresis ± Rituximab
Multiple Cedars-Sinai patent families describe clazakizumab administered simultaneously or sequentially with IVIG, plasmapheresis, and anti-CD20 agents. Plasmapheresis and IVIG remove circulating DSA acutely, while clazakizumab suppresses IL-6-driven plasma cell survival and DSA re-synthesis.
Evidence Base: From Patents to Patient Data
Clazakizumab (anti-IL-6): Multiple Cedars-Sinai patent filings reference human clinical data. HLA-sensitized patients awaiting incompatible kidney transplantation treated with clazakizumab showed reduced or eliminated DSA levels and improved transplant rates. In biopsy-proven cABMR patients (DSA-positive, with transplant glomerulopathy), clazakizumab treatment resulted in stabilized eGFR at 6, 12, and 18 months, reduced inflammatory markers of cABMR, and reduced inflammatory blood markers.
Anti-C5 antibody (eculizumab-class): Retrieved data cite a study of 16 sensitized human kidney transplant recipients, in which only 1/16 (6%) developed acute AMR within the first month compared with approximately 40% of historical controls. However, nearly 50% of patients developed transplant glomerulopathy after cessation of therapy, consistent with historical controls, pointing to the limitation of terminal complement blockade alone. According to EMA and FDA regulatory frameworks, complement inhibitors in transplant settings remain an active area of clinical development.
C1-INH: A Cedars-Sinai patent describes a clinical study in deceased high-risk donor kidney recipients receiving 50 units/kg C1-INH at transplantation and 24 hours post-surgery. While delayed graft function (DGF) rates within the first week did not differ significantly, the C1-INH group showed significantly reduced dialysis requirements at weeks 2 and 4, and significantly improved eGFR at 1 year post-transplant comparable to healthy individuals.
Standard desensitization (IVIG + plasmapheresis + rituximab): A retrieved clinical paper reports 32 patients undergoing desensitization from HLA-incompatible live donors using a multi-component protocol (mean 8±3 plasmapheresis/immunoadsorption sessions), providing the real-world outcomes benchmark against which novel agents are compared. The Transplantation Proceedings literature base documents these standard-of-care outcomes extensively.
Imlifidase (IdeS): Retrieved patent data are preclinical (murine DSA-IgG3 cleavage approximately 80%) and mechanistic. No retrieved clinical outcome papers for imlifidase were identified in this dataset, though the dosing specification (0.01–1 mg/kg, administered ≤6 hours before transplant) from the Hansa Biopharma patent provides translatable clinical parameters. PatSnap's patent analytics tools can track the progression of these preclinical findings toward clinical filings. For further context on transplant immunology, the NIH/NCBI literature database provides extensive background on DSA-mediated rejection mechanisms.
Imlifidase & Kidney Transplant Desensitization — key questions answered
IdeS (Imlifidase), a streptococcal cysteine protease, cleaves human IgG at the lower hinge region, generating F(ab')₂ and Fc fragments. This eliminates Fc-receptor-mediated effector functions, complement fixation via C1q, and antibody-dependent cellular cytotoxicity (ADCC). In sensitized recipients, this cleavage transiently but profoundly reduces functional DSA titers, enabling a crossmatch-negative window for transplantation.
Hansa Biopharma's method patent specifies that a protein with IgG cysteine protease activity (IdeS or MAC2) must be administered no longer than 6 hours before transplantation at 0.01–1 mg/kg body weight to eliminate Fc-receptor binding by substantially all serum IgG molecules.
IL-6 sustains B-cell differentiation into DSA-producing plasma cells and promotes the inflammatory milieu of the allograft. Clazakizumab (anti-IL-6) at subcutaneous doses of approximately 25 mg reduces DSA in HLA-sensitized patients and stabilizes eGFR in cABMR, with biopsy-proven cABMR + transplant glomerulopathy + DSA-positive patients showing reduction in inflammatory markers over 6–18 months.
Retrieved data cite a study of 16 sensitized human kidney transplant recipients given anti-C5 monoclonal antibody after transplantation, in which only 1/16 (6%) developed acute AMR within the first month compared with approximately 40% of historical controls. However, nearly 50% of patients developed transplant glomerulopathy after cessation of therapy, consistent with historical controls, pointing to the limitation of terminal complement blockade alone.
CD38 is highly expressed on long-lived plasma cells producing DSA. Anti-CD38 antibodies such as daratumumab deplete this cellular DSA source, providing a complementary mechanism to DSA-clearance strategies. Cedars-Sinai Medical Center's US patent positions anti-CD38 therapy specifically for patients refractory to IVIG and plasmapheresis (drug-resistant sensitization), representing an escalation strategy in the desensitization cascade.
Retrieved results signal several combination strategies as active development directions: Imlifidase + EndoS (dual-mechanism IgG effector silencing); anti-IL-6 + IVIG + plasmapheresis ± rituximab (Cedars-Sinai protocol); CTLA4-Ig + anti-IL-6/IL-6R without calcineurin inhibitors; anti-C5 + desensitization preconditioning; and IgG protease + gene therapy re-dosing for neutralizing pre-existing anti-vector antibodies.
Still have questions? Let PatSnap Eureka search the patent and literature database for you.
Ask Eureka About Imlifidase & AMRAccelerate Your Transplant Immunology Research
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D. Map the full IgG-cleaving enzyme and AMR patent landscape — assignees, claims, white spaces, and combination strategies — in minutes.
References
- Transplant conditioning regimens — Hansa BioPharma AB, 2023, JP [Patent]
- Methods to enhance organ transplant and antibody therapies — Hansa Biopharma AB, 2024, NZ [Patent]
- IgG Cysteine Proteases — Hansa Biopharma AB, 2018, CL [Patent]
- A Method — Hansa Medical Corporation (Hansa BioPharma predecessor), 2017, CN [Patent]
- Improved IgG Degrading Enzyme and Methods of Use — AstraZeneca (Ireland) Ltd., 2024, CN [Patent]
- Use of clazakizumab to desensitize and improve renal transplantation in HLA-sensitized patients — Cedars-Sinai Medical Center, 2020, WO [Patent]
- Use of clazakizumab to desensitize and improve renal transplantation in HLA-sensitized patients — Cedars-Sinai Medical Center, 2021, US [Patent]
- Clazakizumab in the Treatment of Chronic Antibody-Mediated Rejection of Organ Transplant — Cedars-Sinai Medical Center, 2025, US [Patent]
- Efficacy of an Anti-C5 Antibody in the Prevention of Antibody Mediated Rejection in Sensitized Recipients of a Kidney Transplant — Alexion Pharmaceuticals, 2018, WO/US/JP/EP [Patent]
- Methods of treating antibody-mediated rejection in organ transplant patients with C1-esterase inhibitor — Shire ViroPharma Incorporated, 2016/2020 [Patent]
- Methods of treating antibody-mediated rejection — CSL Behring GmbH, 2023 [Patent]
- Anti-CD38 agents for desensitization and treatment of antibody-mediated rejection of organ transplants — Cedars-Sinai Medical Center, 2022, US [Patent]
- Use of Anti-IL-6 Antibody for Desensitization of Solid Organ Transplant Recipients and/or for Preventing, Stabilizing or Reducing ABMR — Vitaeris Corp., 2019, WO [Patent]
- Type II Anti-CD20 Antibody for Use in Organ Transplantation — Genentech, Inc., 2018 [Patent]
- Kidney transplantation of 32 patients from HLA-incompatible live donors: Efficacy and outcome after desensitization — Servicio de Nefrología, Complexo Hospitalario Universitario A Coruña, 2017 [Paper]
- WIPO — World Intellectual Property Organization — Patent filing database
- European Medicines Agency (EMA) — Complement inhibitor regulatory context
- U.S. Food and Drug Administration (FDA) — Transplant immunology regulatory framework
- NIH/NCBI PubMed — DSA-mediated rejection mechanism literature
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.